- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Hypertension Management in Pre- and Post- Percutaneous Coronary Intervention - An Expert Opinion - Video
Overview
Angiotensin receptor blockers (ARBs) are the most preferred antihypertensive agents among Indian cardiologists for managing hypertension in post-percutaneous coronary intervention (PCI) patients, an Indian expert opinion has revealed.
This first-of-its-kind expert opinion for managing hypertension in patients post PCI and with comorbidities has been published in the Journal of the Practice of Cardiovascular Sciences in April 2024.
336 non-interventional cardiologists and 256 interventional cardiologists participated in the expert opinion creation; which included a questionnaire on post-PCI management, followed by round table meetings.
Some key recommendations from the expert opinion include:
1) In monotherapy, ARBs were the most preferred antihypertensive agents for hypertension patients with different comorbidities*.
2) Metoprolol is the preferred choice among beta-blockers for post-PCI and heart failure patients.
3) Combination therapy with ARBs and beta-blockers is recommended for hypertensive patients with comorbidities.
*Arrhythmia, diabetes, dyslipidemia, HF, and stroke
ARBs: Angiotensin receptor blockers, PCI: Percutaneous Coronary Intervention
Adapted from:
Kumar AS, Kumar V, Shah CP, Kasturi S, Birla A, Revankar S, et al. Hypertension management in pre‑ and post percutaneous coronary intervention patients: An expert opinion of cardiologists from India. J Pract Cardiovasc Sci 2024;10:18-24.